Artwork

Content provided by Back Bay Life Science Advisors, Jonathan P. Gertler, and Peter Bak. All podcast content including episodes, graphics, and podcast descriptions are uploaded and provided directly by Back Bay Life Science Advisors, Jonathan P. Gertler, and Peter Bak or their podcast platform partner. If you believe someone is using your copyrighted work without your permission, you can follow the process outlined here https://player.fm/legal.
Player FM - Podcast App
Go offline with the Player FM app!

The Heart of the Matter: Behind the Renewed Interest in Cardiovascular Disease

24:43
 
Share
 

Manage episode 379625853 series 2991382
Content provided by Back Bay Life Science Advisors, Jonathan P. Gertler, and Peter Bak. All podcast content including episodes, graphics, and podcast descriptions are uploaded and provided directly by Back Bay Life Science Advisors, Jonathan P. Gertler, and Peter Bak or their podcast platform partner. If you believe someone is using your copyrighted work without your permission, you can follow the process outlined here https://player.fm/legal.

A conversation on the rising trends in the cardiology space

Cardiology has historically been a cornerstone of large pharmaceutical portfolios. The late 2000s and 2010s saw many pharmaceutical companies and investors abandon or severely deprioritize cardiology research and development in favor of oncology, immunology, and neurology.

During this episode of The Life Science Report, Dr. Pete Bak and Christian Thienel of Back Bay Life Science Advisors discuss the major players in the industry and novel approaches to future cardiology applications.

Episode topics include:

  • Why pharma’s interest in specialty-like approaches has shifted towards cardiology
  • The promise of “advanced modalities” and gene therapies, such as antisense oligonucleotides (ASOs) and small interfering RNA (siRNA)
  • How these newer treatments stack up against traditional small molecule orals, like statins
  • Clinical stage pipeline analysis across cardiology and visible trends on the horizon

This is the 20th episode of Back Bay’s podcast, covering all facets of healthcare development and transactions. For questions, be in touch: www.bblsa.com

  continue reading

28 episodes

Artwork
iconShare
 
Manage episode 379625853 series 2991382
Content provided by Back Bay Life Science Advisors, Jonathan P. Gertler, and Peter Bak. All podcast content including episodes, graphics, and podcast descriptions are uploaded and provided directly by Back Bay Life Science Advisors, Jonathan P. Gertler, and Peter Bak or their podcast platform partner. If you believe someone is using your copyrighted work without your permission, you can follow the process outlined here https://player.fm/legal.

A conversation on the rising trends in the cardiology space

Cardiology has historically been a cornerstone of large pharmaceutical portfolios. The late 2000s and 2010s saw many pharmaceutical companies and investors abandon or severely deprioritize cardiology research and development in favor of oncology, immunology, and neurology.

During this episode of The Life Science Report, Dr. Pete Bak and Christian Thienel of Back Bay Life Science Advisors discuss the major players in the industry and novel approaches to future cardiology applications.

Episode topics include:

  • Why pharma’s interest in specialty-like approaches has shifted towards cardiology
  • The promise of “advanced modalities” and gene therapies, such as antisense oligonucleotides (ASOs) and small interfering RNA (siRNA)
  • How these newer treatments stack up against traditional small molecule orals, like statins
  • Clinical stage pipeline analysis across cardiology and visible trends on the horizon

This is the 20th episode of Back Bay’s podcast, covering all facets of healthcare development and transactions. For questions, be in touch: www.bblsa.com

  continue reading

28 episodes

All episodes

×
 
Loading …

Welcome to Player FM!

Player FM is scanning the web for high-quality podcasts for you to enjoy right now. It's the best podcast app and works on Android, iPhone, and the web. Signup to sync subscriptions across devices.

 

Quick Reference Guide